Estrogen Use in Protection From Cognitive Decline
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00097058|
Recruitment Status : Completed
First Posted : November 18, 2004
Last Update Posted : November 19, 2014
|Condition or disease|
A total of 71 postmenopausal women ages 50-65 on estrogen therapy will be randomized to continue or discontinue use of estrogen and will be followed for two years.
Participants will undergo PET and MRI scans and neuropsychological assessments initially and at the end of the two-year follow-up period. These procedures will allow us to evaluate brain metabolism and cognitive performance at baseline and two years following continuation or discontinuation of estrogen therapy.
We hypothesize that women who discontinue estrogen will show more evidence of decline than those who continue estrogen. This project will expand current knowledge of effects of estrogen by 1) determining whether estrogen use among postmenopausal women at risk for cognitive decline is protective of brain metabolism, 2) identifying early predictors for cognitive decline, and 3) developing guidelines for estrogen use in postmenopausal women.
|Study Type :||Observational|
|Estimated Enrollment :||71 participants|
|Official Title:||Estrogen Use in Protection From Cognitive Decline|
|Study Start Date :||August 2003|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
Continue current hormone therapy
Taper off hormone therapy
- Changes in cognition and brain metabolism [ Time Frame: Baseline and 24 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00097058
|United States, California|
|Stanford University School of Medicine, Dept. of Psychiatry and Behavioral Sciences|
|Stanford, California, United States, 94070-5723|
|Principal Investigator:||Natalie Rasgon, MD, PhD||Stanford University School of Medicine, Dept of Psychiatry and Behavioral Sciences|
|Principal Investigator:||Terence Ketter, MD||Stanford University|
|Principal Investigator:||Jerome Yesavage, MD||Stanford University|
|Principal Investigator:||Jennifer Hoblyn, MD||VA Palo Alto Health Care System|